Exiqon A/S (NASDAQ OMX: EXQ.CO), a leading supplier of high-value gene
expression analysis products, today announced the appointment of a Center of
Excellence as part of its new certified service provider program. The Center of
Excellence program is introduced in response to an increased demand for
Exiqon's LNA™ (Locked Nucleic Acid) products and services.

The Oncogenomics Core Facility (OCF) at the Sylvester Comprehensive Cancer
Center at the University of Miami Miller School of Medicine will offer
real-time PCR services based on the Exiqon miRCURY LNA™ Universal RT microRNA
PCR product line.

LNA™-based microRNA profiling holds great promise as a non-invasive way to
discover important new biomarkers for a wide range of diseases and biological
processes. The extreme sensitivity obtained by inclusion of LNA™ in the PCR
primers enables the use of non-invasive samples like serum and plasma where the
quantity of RNA is extremely low.

“The Oncogenomics Core Facility has had great success over the last several
months using the Exiqon LNA qPCR platform and we are excited to be a Center of
Excellence”, said Toumy Guettouche, Ph.D., Core Director.

“We are pleased to announce the first Center of Excellence in North America”,
said Henrik M Pfundheller, Ph.D., SVP Sales & Marketing and added: “The demand
for profiling microRNAs from body fluids such as serum/plasma and urine is
increasing at a fast rate and we are therefore happy to have the Oncogenomics
Core Facility as part of our program”.

Exiqon plans to announce additional Centers of Excellence in the upcoming
months.

Additional information:

Lars Kongsbak, CEO,
tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, Senior Vice President Sales & Marketing,
tel. +45 4565 0420 (cell: +45 4090 2106)

See the full press release in the attached PDF or at
www.exiqon.com/investor/portal.

PressRelease_August2011_CoE_University of Miami.pdf